Atypical Chryseobacterium meningosepticum and Meningitis and Sepsis in Newborns and the Immunocompromised, Taiwan
Cheng-Hsun Chiu*

, Michael Waddingdon†, Wu-Shiun Hsieh*, David E. Greenberg‡, Paul C. Schreckenberger§, and Amy M. Carnahan¶
Author affiliations: *Chang Gung Children's Hospital, Taoyuan, Taiwan; †Accugenix, Inc., Newark, Delaware; ‡British Columbia's Children's Hospital, Vancouver, British Columbia, Canada; §University of Illinois at Chicago Medical Center, Chicago, Illinois, USA; ¶University of Maryland School of Medicine, Baltimore, Maryland, USA
Main Article
Table 2
Comparative in vitro activity of various antibiotics against 17 strains of atypical Chryseobacterium meningosepticum
|
|
MIC (µg/mL) |
|
Antibiotics |
Range |
MIC50 |
MIC90 |
Ampicillin |
16-64 |
32 |
32 |
Ticarcillin |
32->128 |
128 |
>128 |
Piperacillin |
1-128 |
8 |
32 |
Cephalothin |
32->32 |
32 |
32 |
Cefamandole |
16->32 |
>32 |
>32 |
Cefotaxime |
8->32 |
32 |
>32 |
Ceftriaxone |
8->32 |
16 |
32 |
Imipenem |
1->32 |
32 |
32 |
Ceftazidime |
2-64 |
16 |
>32 |
Gentamicin |
16-64 |
32 |
64 |
Amikacin |
2-64 |
64 |
64 |
Ciprofloxacin |
0.25-16 |
1 |
4 |
Main Article
Page created: December 17, 2010
Page updated: December 17, 2010
Page reviewed: December 17, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.